NASDAQ·In Vitro & In Vivo Diagnostic Substances

IMDXInsight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc. (IMDX) has delinquent SEC filing, delisting / deregistration notice, and auditor change flags.

Last filing: filing·May 13, 2026EDGAR ↗

IMDX Cash Runway

Months-of-runway analysis for IMDX, derived directly from SEC XBRL: latest cash and operating cash flow, monthly burn rate, runway under current conditions. Historical trend + verbatim citation panel ships in Phase 2.

Coming in Phase 2

The dedicated per-ticker cash-runway page will surface a 6-8 quarter trend with the underlying us-gaap:CashAndCashEquivalentsAtCarryingValue + us-gaap:NetCashProvidedByUsedInOperatingActivities citations alongside each data point. In the meantime, see the ranked cross-company view:

All companies ranked by months-of-runway →

Related on IMDX

Share-count dilution →

Dilution is the natural counterpart to runway burn.

Going-concern history →

Auditor + management language across filings.